Trial Profile
A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs NUC 7738 (Primary) ; Pembrolizumab
- Indications B-cell lymphoma; Colorectal cancer; Gastric cancer; Hodgkin's disease; Lung cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Skin cancer; Solid tumours; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms NuTide: 701
- Sponsors NuCana
- 25 Mar 2024 According to a NuCana media release,in 2024, NuCana expects to announce data from this study.
- 16 Oct 2023 According to a NuCana media release, data from this study were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 that took place October 11-15, 2023 in Boston, Massachusetts.
- 16 Oct 2023 Results presented in a NuCana Media Release.